3,4-Bis(benzyloxy)benzaldehyde-Derived Hydrazones: Synthesis, α-Amylase-Selective Inhibition, Antioxidant Profiling, and In Silico Evaluation

Carbohydrate-hydrolyzing enzymes (α-amylase and α-glucosidase) are clinically validated targets for controlling postprandial hyperglycemia in type 2 diabetes mellitus (T2DM), and oxidative stress is a recognized contributor to disease progression. Herein, a series of hydrazone Schiff bases derived from 3,4-bis(benzyloxy)benzaldehyde were synthesized by acid-catalyzed condensation of the aldehyde with para-substituted phenylhydrazines and were characterized by 1H and 13C NMR spectroscopy, FT-IR spectroscopy, and high-resolution mass spectrometry; chromatographic purity was established by RP-HPLC (94.5–98.6 area % at 350 nm). The series was evaluated for in vitro inhibition of porcine pancreatic α-amylase and yeast α-glucosidase and for antioxidant capacity using four complementary assays (DPPH, ABTS, FRAP, and CUPRAC). The compounds displayed a pronounced α-amylase preference: compound 9 (IC50 = 160.40 ± 2.05 μg/mL) and compound 7 (IC50 = 166.01 ± 2.64 μg/mL) were the most potent and exceeded acarbose under the assay conditions (IC50 = 232.66 ± 4.93 μg/mL); on a molar basis, both are essentially equipotent with the reference drug (345.2 ± 4.4 and 378.6 ± 6.0 μM versus 360.4 ± 7.6 μM), and IC50 values are reported in both units throughout (Table 1). α-Glucosidase inhibition was moderate, with the para-chloro analogue 3 being the most active (IC50 = 83.13 ± 6.53 μg/mL; 187.7 ± 14.7 μM). The selectivity index (IC50 α-glucosidase/IC50 α-amylase) spans 0.22 for 3 to 2.38 for 9, so a single para-substituent determines which carbohydrase is preferred. Antioxidant behavior was assay-dependent: compounds 1 and 4 delivered the highest ferric-reducing power (FRAP = 1854.0 ± 1.5 and 1786.7 ± 5.2 μmol Fe2+/g), and compound 5 gave the strongest CUPRAC response (280.95 ± 3.43 mg GAE/g). Molecular docking against α-amylase (PDB 1B2Y) and α-glucosidase (PDB 3TOP), together with SwissADME, QikProp, and ADMETlab profiling, provides a structural rationale for the observed substituent effects. These results define a clear, substituent-driven selectivity relationship within a lipophilic dibenzyloxy hydrazone framework and establish the DBZO-hydrazone scaffold as a tractable system for further optimization.

Authors

Institutions

Publication Details

Journal
ACS Omega
Published
2026-11-19
DOI
https://doi.org/10.1021/acsomega.6c07978
Primary Topic
Natural Antidiabetic Agents Studies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

3,4-Bis(benzyloxy)benzaldehyde-Derived Hydrazones: Synthesis, α-Amylase-Selective Inhibition, Antioxidant Profiling, and In Silico Evaluation

İsmail Çeli̇k, Leyla Paşayeva, Hanifa Fatullayev
ACS Omega
Natural Antidiabetic Agents Studies
article

3,4-Bis(benzyloxy)benzaldehyde-Derived Hydrazones: Synthesis, α-Amylase-Selective Inhibition, Antioxidant Profiling, and In Silico Evaluation

İsmail Çeli̇k, Leyla Paşayeva, Hanifa Fatullayev
article en

Abstract

Carbohydrate-hydrolyzing enzymes (α-amylase and α-glucosidase) are clinically validated targets for controlling postprandial hyperglycemia in type 2 diabetes mellitus (T2DM), and oxidative stress is a recognized contributor to disease progression. Herein, a series of hydrazone Schiff bases derived from 3,4-bis(benzyloxy)benzaldehyde were synthesized by acid-catalyzed condensation of the aldehyde with para-substituted phenylhydrazines and were characterized by 1H and 13C NMR spectroscopy, FT-IR spectroscopy, and high-resolution mass spectrometry; chromatographic purity was established by RP-HPLC (94.5–98.6 area % at 350 nm). The series was evaluated for in vitro inhibition of porcine pancreatic α-amylase and yeast α-glucosidase and for antioxidant capacity using four complementary assays (DPPH, ABTS, FRAP, and CUPRAC). The compounds displayed a pronounced α-amylase preference: compound 9 (IC50 = 160.40 ± 2.05 μg/mL) and compound 7 (IC50 = 166.01 ± 2.64 μg/mL) were the most potent and exceeded acarbose under the assay conditions (IC50 = 232.66 ± 4.93 μg/mL); on a molar basis, both are essentially equipotent with the reference drug (345.2 ± 4.4 and 378.6 ± 6.0 μM versus 360.4 ± 7.6 μM), and IC50 values are reported in both units throughout (Table 1). α-Glucosidase inhibition was moderate, with the para-chloro analogue 3 being the most active (IC50 = 83.13 ± 6.53 μg/mL; 187.7 ± 14.7 μM). The selectivity index (IC50 α-glucosidase/IC50 α-amylase) spans 0.22 for 3 to 2.38 for 9, so a single para-substituent determines which carbohydrase is preferred. Antioxidant behavior was assay-dependent: compounds 1 and 4 delivered the highest ferric-reducing power (FRAP = 1854.0 ± 1.5 and 1786.7 ± 5.2 μmol Fe2+/g), and compound 5 gave the strongest CUPRAC response (280.95 ± 3.43 mg GAE/g). Molecular docking against α-amylase (PDB 1B2Y) and α-glucosidase (PDB 3TOP), together with SwissADME, QikProp, and ADMETlab profiling, provides a structural rationale for the observed substituent effects. These results define a clear, substituent-driven selectivity relationship within a lipophilic dibenzyloxy hydrazone framework and establish the DBZO-hydrazone scaffold as a tractable system for further optimization.

ACS Omega
Erciyes University (TR)
Natural Antidiabetic Agents Studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon